Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $6.64 Consensus Target Price from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have been given a consensus rating of "Hold" by the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $6.64.

MRVI has been the topic of several recent research reports. UBS Group reduced their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a research report on Friday, March 21st. Baird R W cut Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Craig Hallum dropped their price objective on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Robert W. Baird dropped their price objective on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th.

Maravai LifeSciences Price Performance

Shares of Maravai LifeSciences stock traded down $0.15 during trading on Friday, hitting $2.25. 2,428,954 shares of the stock traded hands, compared to its average volume of 2,352,123. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The stock has a market cap of $572.99 million, a price-to-earnings ratio of -1.37 and a beta of 0.19. The firm's fifty day moving average is $2.08 and its 200-day moving average is $3.95. Maravai LifeSciences has a 52 week low of $1.67 and a 52 week high of $11.50.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The company had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. The business's revenue for the quarter was down 26.9% on a year-over-year basis. Research analysts expect that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. McAdam LLC purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at approximately $31,000. Jane Street Group LLC lifted its stake in shares of Maravai LifeSciences by 1,463.1% in the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company's stock valued at $841,000 after purchasing an additional 356,067 shares during the period. Ascent Group LLC purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at approximately $41,000. Clearline Capital LP lifted its stake in shares of Maravai LifeSciences by 9.6% in the 1st quarter. Clearline Capital LP now owns 205,339 shares of the company's stock valued at $454,000 after purchasing an additional 18,000 shares during the period. Finally, Voleon Capital Management LP purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at approximately $296,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.